Contact
Home • Insights • Assessing the market for a novel gene therapy

Assessing the market for a novel gene therapy

Less than 1 min read

The Challenge

Our client was preparing for the launch of a novel gene therapy and was looking to understand the potential value of its product in the market. They also wanted to know the best ways to balance patient and alternative pricing models across different countries.

The Approach

Putnam, an Ashfield Advisory company, created market segments for the new therapy and estimated patient costs based on dosing. The team also gauged the likely price leverage at launch and the expected price decrease as the product expands.

They put together detailed expectations and requirements across different markets and assessed the need for specific alternative pricing models.

The Results

Based on Putnam’s work, the client has decided to move forward with innovative pricing models, tailored by market.

Insights

Other similar insights

See all insights

3 trends shaping commercialization in the cell and gene therapy sector

Disharee Nath, PhD, Associate Medical Director at Mind+Matter, attended the two-day Cell & Gene Therapy USA (Sep ’21) conference organized by Reuters.

Read more

Improving patient experience in Cell and Gene Therapies through a data-centric approach

Cell and gene therapies (C&GTs) continue to expand with 3,366 currently in preclinical and clinical development.

Read more